Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-546P (RNA, U6 small nuclear 546, pseudogene) is a classified pseudogene in the human genome and is not translated into a functional RNA or protein. It is derived from the U6 snRNA family, specifically mirroring the RNA sequence involved in the core spliceosomal complex responsible for pre-mRNA intron excision in eukaryotes. Pseudogenes like RNU6-546P are usually the result of gene duplication or retrotransposition events and do not produce the small U6 snRNA that participates in spliceosome catalytic activity. The presence of many U6-derived pseudogenes across the genome illustrates evolutionary redundancy, but these copies lack biological activity and are not implicated in disease, signal transduction, or as drug targets. Only the functional U6 snRNA (not pseudogenes) is directly involved in pre-mRNA splicing within the nucleus. Summary clarification: RNU6-546P is not a therapeutic target, has no disease relevance or drug interaction, functions solely as genomic redundancy, and is accurately described as a pseudogene derived from the U6 small nuclear RNA family.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 546, pseudogene (RNU6-546P).